Development of a Pharmacokinetic (PK) Model and Assessment of Patient (Pt) Covariate Effects on Dose-Dependent PK Following Different Dosing Schedules in Two Phase I Trials of AP23573 (AP), a mTOR Inhibitor
Journal of Clinical Oncology - United States
doi 10.1200/jco.2005.23.16_suppl.3043
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2005
Authors
Publisher
American Society of Clinical Oncology (ASCO)